Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Poseida Therapeutics, Inc. email format Poseida Therapeutics, Inc. management contacts

Related company profiles:

Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing.

Company Details

Employees
218
Founded
-
Address
9390 Towne Centre Dr,
Phone
(858)-779-3100
Email
in****@****ida.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
poseida.com
Keywords
Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative Medicine, T-cells, Allogeneic, Oncology, Immuno-oncology, Immunology, Poseida, Cytotoxic T Lymphocytes, piggyBac®, piggyBac® DNA Modification System, Cas-CLOVER™, TAL-CLOVER™.
HQ
San Diego, California
Competitors
Crinetics Pharmaceuticals, Vertex Pharmaceuticals, Sarepta Therapeutics, Mirati Therapeutics, Capstan Therapeutics, Avidity Biosciences, Inc., Neurocrine Biosciences, Acadia Pharmaceuticals Inc., Fate Therapeutics Inc., Ionis Pharmaceuticals, Inc..
Looking for a particular Poseida Therapeutics, Inc. employee's phone or email?

Poseida Therapeutics, Inc. Questions

News

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PR Newswire

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. PR Newswire

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PR Newswire

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting PR Newswire

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive®

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study CGTLive®

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PR Newswire

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline PR Newswire

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 PR Newswire

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - PR Newswire

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche PR Newswire

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy - PR Newswire

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy PR Newswire

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema PR Newswire

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PR Newswire

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients PR Newswire

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR Newswire

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies PR Newswire

Poseida Therapeutics Announces Board Change - PR Newswire

Poseida Therapeutics Announces Board Change PR Newswire

Poseida Therapeutics Announces Leadership Transition - PR Newswire

Poseida Therapeutics Announces Leadership Transition PR Newswire

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - PR Newswire

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PR Newswire

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma - PR Newswire

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma PR Newswire

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer - PR Newswire

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer PR Newswire

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies - PR Newswire

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies PR Newswire

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy - PR Newswire

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy PR Newswire

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones - PR Newswire

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones PR Newswire

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma - PR Newswire

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma PR Newswire

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting - PR Newswire

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting PR Newswire

Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive®

Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma CGTLive®

Allogeneic CAR T-cell therapy: the future of cancer care - Drug Target Review

Allogeneic CAR T-cell therapy: the future of cancer care Drug Target Review

Poseida Therapeutics Raises $142 Million in Series C Financing - GlobeNewswire

Poseida Therapeutics Raises $142 Million in Series C Financing GlobeNewswire

Roche enters into a definitive agreement to acquire Poseida - GlobeNewswire

Roche enters into a definitive agreement to acquire Poseida GlobeNewswire

Poseida Therapeutics Receives Regenerative Medicine - GlobeNewswire

Poseida Therapeutics Receives Regenerative Medicine GlobeNewswire

Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies - GlobeNewswire

Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies GlobeNewswire

Poseida Awarded $19.8 Million CIRM Grant to Support - GlobeNewswire

Poseida Awarded $19.8 Million CIRM Grant to Support GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies - GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

Companies like Poseida Therapeutics, Inc.

Acadia Pharmaceuticals Inc. logo - Similar company to Poseida Therapeutics, Inc.

Acadia Pharmaceutica...

891
Neurocrine Biosciences logo - Similar company to Poseida Therapeutics, Inc.

Neurocrine Biosciences

1.98K
Crinetics Pharmaceuticals logo - Similar company to Poseida Therapeutics, Inc.

Crinetics Pharmaceut...

510
Avidity Biosciences, Inc. logo - Similar company to Poseida Therapeutics, Inc.

Avidity Biosciences,...

491
Capstan Therapeutics logo - Similar company to Poseida Therapeutics, Inc.

Capstan Therapeutics

107
Ionis Pharmaceuticals, Inc. logo - Similar company to Poseida Therapeutics, Inc.

Ionis Pharmaceutical...

1.27K
Mirati Therapeutics logo - Similar company to Poseida Therapeutics, Inc.

Mirati Therapeutics

60
Sarepta Therapeutics logo - Similar company to Poseida Therapeutics, Inc.

Sarepta Therapeutics

1.37K
Vertex Pharmaceuticals logo - Similar company to Poseida Therapeutics, Inc.

Vertex Pharmaceuticals

6.09K
Fate Therapeutics Inc. logo - Similar company to Poseida Therapeutics, Inc.

Fate Therapeutics Inc.

242

Top Poseida Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant